DragonVenture Chosen by Biopharmaceutical Company Zengen to Provide Consulting Services

Palo Alto, Calif. September 10, 2002

Silicon Valley based cross-Pacific consulting and venture capital firm DragonVenture, Inc. today announced it has been chosen by Zengen to provide consulting services to assist Zengen in tapping into the immense Chinese pharmaceutical and over-the-counter health product markets.

Zengen is a biopharmaceutical company focused on discovering, developing and commercializing innovative products to treat and prevent infection and inflammation through application of its patented peptide technologies. Zengen’s strategy is to demonstrate the capabilities of its technologies and, where appropriate, enter into collaborative arrangements with other pharmaceutical companies that possess complementary capabilities, development resources or other assets. Because China’s biopharmaceutical industry shows signs of exponential growth, both Zengen and DragonVenture believe this is the right time to enter the vast China market.

“It is not a question of whether a biopharmaceutical company should enter the Chinese market,” says R. Steven Davidson, Ph.D., President and CEO of Zengen, “rather, it is a question of whether a company can afford not to enter the China market.” Tony C. Luh, Managing Director of DragonVenture, adds, “we are excited at this unique opportunity to assist Zengen in penetrating the huge and relatively untapped China market. China’s biopharmaceutical industry represents huge potential and upside for Zengen.”

Under the terms of their agreement, DragonVenture will advise Zengen on its international expansion on many fronts. DragonVenture will identify and introduce Zengen to well-established drug and health care industry partners in China. In addition, it will provide Zengen with strategic advice on the best ways to approach such partners in China and engage in meaningful business discussions. DragonVenture’s advisory role also includes consulting Zengen on removing cultural and language barriers that may arise during Zengen’s China-entry endeavors.

About Zengen Inc

Zengen, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative products to treat and prevent infection and inflammation through application of its patented peptide technologies. These technologies are based on an extensive background of over 25 years of academic research on peptide molecules derived from a-Melanocyte-Stimulating Hormone (a-MSH), an endogenous molecule that modulates inflammatory and immune responses.

Zengen was incorporated in California in May 1999. The Company's principal executive offices are located at 6429 Independence Avenue, Woodland Hills, California 91367. For more information about Zengen, please visit www.zengen.com.

About DragonVenture, Inc.

DragonVenture Inc. is a premier cross-Pacific venture capital, consulting, mergers and acquisitions company specializing in bridging the U.S. and Greater China marketplaces. DragonVenture manages funds that invest in emerging companies in the areas of telecommunications, Internet infrastructure, IC & Semiconductor, and Linux. The company provides cross-Pacific consulting services and facilitates cross-Pacific strategic alliances and/or partnerships, and mergers and acquisitions through DragonVenture's M&A Fund. DragonVenture, Inc. is headquartered in Silicon Valley and also has a branch office in Beijing, China. DragonVenture is working closely with numerous U. S. firms on their China strategy while assisting a handful of Greater China companies to expand business horizons into North America. For more information about DragonVenture, Inc. visit www.dragonventure.com or www.dragonventure.com.cn